The convergence of biology and artificial intelligence, or bio-integrated AI, is set to revolutionize US biotech and pharma by 2026. This post delves into the transformative opportunities, from accelerating drug discovery to enabling truly personalized medicine, and outlines the strategic imperatives for industry leaders.